Journal article
D. Hormuth, Angela M. Jarrett, E. Lima, M. McKenna, D. Fuentes, T. Yankeelov
JCO Clinical Cancer Informatics, 2019
JCO Clinical Cancer Informatics, 2019
Semantic Scholar
DOI
PubMed
Cite
Cite
APA
Click to copy
Hormuth, D., Jarrett, A. M., Lima, E., McKenna, M., Fuentes, D., & Yankeelov, T. (2019). Mechanism-Based Modeling of Tumor Growth and Treatment Response Constrained by Multiparametric Imaging Data. JCO Clinical Cancer Informatics.
Chicago/Turabian
Click to copy
Hormuth, D., Angela M. Jarrett, E. Lima, M. McKenna, D. Fuentes, and T. Yankeelov. “Mechanism-Based Modeling of Tumor Growth and Treatment Response Constrained by Multiparametric Imaging Data.” JCO Clinical Cancer Informatics (2019).
MLA
Click to copy
Hormuth, D., et al. “Mechanism-Based Modeling of Tumor Growth and Treatment Response Constrained by Multiparametric Imaging Data.” JCO Clinical Cancer Informatics, 2019.
BibTeX Click to copy
@article{d2019a,
title = {Mechanism-Based Modeling of Tumor Growth and Treatment Response Constrained by Multiparametric Imaging Data.},
year = {2019},
journal = {JCO Clinical Cancer Informatics},
author = {Hormuth, D. and Jarrett, Angela M. and Lima, E. and McKenna, M. and Fuentes, D. and Yankeelov, T.}
}
Abstract
Multiparametric imaging is a critical tool in the noninvasive study and assessment of cancer. Imaging methods have evolved over the past several decades to provide quantitative measures of tumor and healthy tissue characteristics related to, for example, cell number, blood volume fraction, blood flow, hypoxia, and metabolism. Mechanistic models of tumor growth also have matured to a point where the incorporation of patient-specific measures could provide clinically relevant predictions of tumor growth and response. In this review, we identify and discuss approaches that use multiparametric imaging data, including diffusion-weighted magnetic resonance imaging, dynamic contrast-enhanced magnetic resonance imaging, diffusion tensor imaging, contrast-enhanced computed tomography, [18F]fluorodeoxyglucose positron emission tomography, and [18F]fluoromisonidazole positron emission tomography to initialize and calibrate mechanistic models of tumor growth and response. We focus the discussion on brain and breast cancers; however, we also identify three emerging areas of application in kidney, pancreatic, and lung cancers. We conclude with a discussion of the future directions for incorporating multiparametric imaging data and mechanistic modeling into clinical decision making for patients with cancer.
